

Product Name: JNJ-7706621 Revision Date: 01/10/2021

NH<sub>2</sub>

# **Product Data Sheet**

HN

H<sub>2</sub>N

# JNJ-7706621

Cat. No.:	A4115
CAS No.:	443797-96-4
Formula:	C15H12F2N6O3S
M.Wt:	394.36
Synonyms:	JNJ7706621, JNJ 7706621
Target:	Chromatin/Epigenetics
Pathway:	Aurora Kinase
Storage:	Store at -20°C
	<b>al0</b>

## Solvent & Solubility

	insoluble in EtOH; insoluble in H2O; $\geq$ 19.7 mg/mL in DMSO				
Preparing In Vitro Stock Solutions		Mass Solvent Concentration	1mg	5mg	10mg
	Slock Solutions	1 mM	2.5358 mL	12.6788 mL	25.3575 mL
	810	5 mM	0.5072 mL	2.5358 mL	5.0715 mL
	PELL	10 mM	0.2536 mL	1.2679 mL	2.5358 mL

Please refer to the solubility information to select the appropriate solvent.

## **Biological Activity**

Shortsummary	Potent CDK/Aurora kinase inhibitor
--------------	------------------------------------

IC<sub>50</sub> & Target

In Vitro

9 nM (CDK1), 4 nM (CDK2), 11 nM (Aurora A), 15 nM (Aurora B)

C	ell Viability Assay	

Cell viability Assay	The second s
Cell Line:	U937 cells
Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining
	a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or
	shake it in the ultrasonic bath for a while. Stock solution can be stored below
	-20 °C for several months.
Reacting conditions:	0, 0.5, 1, 2, 3 or 4 μM; 24 hrs

1 | www.apexbt.com

	Applications:	In U937 cells, JNJ-7706621 time- and dose-dependently induced cell		
		apoptosis.		
	Animal experiment			
In Vivo	Animal models:	Mouse xenograft model of A375 melanoma human tumor		
	Dosage form:	100 or 125 mg/kg; p.o. or i.p.		
	Applications:	In mouse xenograft model of A375 melanoma human tumor, JNJ-7706621 at the dose of 100 or 125 mg/kg caused tumor regression.		
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility m slightly differ with the theoretical value. This is caused by an experimen system error and it is normal.		

#### **Product Citations**

1. Zhong S, Wu B, et al. "Identification of Driver Genes and Key Pathways of Glioblastoma Shows JNJ-7706621 as a Novel Antiglioblastoma Drug." World Neurosurg. 2018 Jan;109:e329-e342.PMID:28989042

See more customer validations on www.apexbt.com.

#### References

[1]. Stuart Emanuel, Catherine A. Rugg, Robert H. Gruninger, Ronghui Lin, Angel Fuentes-Pesquera, Peter J. Connolly, Steven K. Wetter, Beth Hollister, Walter W. Kruger, Cheryl Napier, Linda Jolliffe, and Steven A. Middleton. The In vitro and In vivo Effects of JNJ-7706621: A Dual Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases. Cancer Res 2005;65:9038-9046.

### Caution

#### FOR RESEARCH PURPOSES ONLY. NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

#### **APExBIO Technology**

2 | www.apexbt.com

#### www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

